

Special Issue

Enzyme Inhibitors: Potential Therapeutic Approaches

Message from the Guest Editor

Enzymes are involved in all biochemical processes; thus, they constitute the second greatest drug target after receptors. The dysregulation of enzyme activity has been related to several pathologic disorders. Apart from specific cases which demand enzyme administration to counteract the lack or reduced action of an enzyme, small molecules that moderate enzyme activity are broadly used. However, the enhancement of enzyme expression or activity is the aim in only certain cases, while enzyme inhibition is the most common drug target. Inhibitors of human enzymes are used to fight many common disorders, such as inflammation, hypertension and hypercholesterolemia, and are one of the medications for the treatment of diabetes. Moreover, most antiviral, antibacterial and antifungal agents also act as enzyme inhibitors.

This Special Issue aims to gather research and review articles on enzymes and enzyme inhibitors with pharmaceutical interest, covering a hot and developing area of medical research.

Guest Editor

Prof. Dr. Phaedra Eleftheriou

Department of Biomedical Sciences, School of Health Sciences,
International Hellenic University, 57400 Thessaloniki, Greece

Deadline for manuscript submissions

closed (25 October 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/139829

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)